Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | K.R. Webster, V. K Goel, I. NJ Hung, G. S Parker, J.Staunton, M. Neal, J. Molter, G.G Chiang, K. A. Jessen, C. J Wegerski, S. Sperry, V. Huang, J. Chen, P. A Thompson, J. R Appleman, S. E Webber, P. A Sprengeler, S. H Reich | ||||||||||||
Title | eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL) | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/126/23/1554 | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Tomivosertib | Tomivosertib | 0 | 6 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tomivosertib | eFT508|EFT-508 | MNK1/2 Inhibitor 3 | Tomivosertib (eFT508) inhibits MNK1 and MNK2, potentially resulting in decreased tumor cell proliferation and tumor growth, and disrupts translation of PD-L1 (CD274) through inhibition of EIF4E phosphorylation (PMID: 30643286). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|